ROTH Capital lifts Seelos Therapeutics Inc. [SEEL] price estimate. Who else is bullish?

Related

Seelos Therapeutics Inc. [NASDAQ: SEEL] stock went on an upward path that rose over 1.21% on Wednesday, amounting to a one-week price decrease of less than 0.00%. The company report on December 21, 2021 that Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and granted as an inducement material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4).


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The stock option has an exercise price equal to $1.65, the closing price per share of Seelos’ common stock, as reported by Nasdaq, on December 20, 2021, the date of grant. The option is a non-qualified stock option and 1/4th of the shares vest on the one-year anniversary of the new employee’s commencement of employment and an additional 1/48th of the shares vest monthly thereafter over the next three years, in each case provided that the new employee remains continuously employed by Seelos through the applicable vesting date, inclusive.

Over the last 12 months, SEEL stock rose by 14.38%. The one-year Seelos Therapeutics Inc. stock forecast points to a potential upside of 82.42. The average equity rating for SEEL stock is currently 1.80, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $164.95 million, with 102.33 million shares outstanding and 97.38 million shares in the current float. Compared to the average trading volume of 3.43M shares, SEEL stock reached a trading volume of 2684477 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Seelos Therapeutics Inc. [SEEL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SEEL shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SEEL stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Seelos Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 27, 2021. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on July 01, 2021, representing the official price target for Seelos Therapeutics Inc. stock. Previously, the target price had yet another raise to $10, while Cantor Fitzgerald analysts kept a Overweight rating on SEEL stock.

The Average True Range (ATR) for Seelos Therapeutics Inc. is set at 0.14 The Price to Book ratio for the last quarter was 2.35, with the Price to Cash per share for the same quarter was set at 0.78.

SEEL Stock Performance Analysis:

Seelos Therapeutics Inc. [SEEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, SEEL shares dropped by -4.02% in over the last four-week period, additionally sinking by -36.74% over the last 6 months – not to mention a rise of 14.38% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 43.32, with the RSI for the last a single of trading hit 45.17, and the three-weeks RSI is set at 42.73 for Seelos Therapeutics Inc. [SEEL]. The present Moving Average for the last 50 days of trading for this stock 1.9460, while it was recorded at 1.6880 for the last single week of trading, and 2.9268 for the last 200 days.

Insight into Seelos Therapeutics Inc. Fundamentals:

Return on Total Capital for SEEL is now -305.30, given the latest momentum, and Return on Invested Capital for the company is -387.52. Return on Equity for this stock declined to -1,489.36, with Return on Assets sitting at -133.62. When it comes to the capital structure of this company, Seelos Therapeutics Inc. [SEEL] has a Total Debt to Total Equity ratio set at 378.07. Additionally, SEEL Total Debt to Total Capital is recorded at 79.08, with Total Debt to Total Assets ending up at 55.58. Long-Term Debt to Equity for the company is recorded at 283.55, with the Long-Term Debt to Total Capital now at 59.31.

Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc. [SEEL] managed to generate an average of -$1,910,100 per employee.Seelos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.10 and a Current Ratio set at 10.10.

>> 7 Top Picks for the Post-Pandemic Economy <<

Seelos Therapeutics Inc. [SEEL] Insider Position Details

There are presently around $66 million, or 42.30% of SEEL stock, in the hands of institutional investors. The top three institutional holders of SEEL stocks are: BLACKROCK INC. with ownership of 6,382,949, which is approximately 19.49% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 5,177,503 shares of the stock with an approximate value of $8.54 million in SEEL stocks shares; and WOODLINE PARTNERS LP, currently with $7.23 million in SEEL stock with ownership of nearly 43.849% of the company’s market capitalization.

Positions in Seelos Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 62 institutional holders increased their position in Seelos Therapeutics Inc. [NASDAQ:SEEL] by around 6,595,090 shares. Additionally, 44 investors decreased positions by around 7,277,134 shares, while 22 investors held positions by with 26,298,086 shares. The mentioned changes placed institutional holdings at 40,170,310 shares, according to the latest SEC report filing. SEEL stock had 23 new institutional investments in for a total of 1,200,398 shares, while 18 institutional investors sold positions of 2,266,929 shares during the same period.